Rosuvastatin: A new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia

Heart Disease

Volumn 5, Issue 1, 2003, Pages 72-78

  Cheng Lai, Angela ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; ERYTHROMYCIN; FLUCONAZOLE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; FLU LIKE SYNDROME; FOOD DRUG INTERACTION; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY FUNCTION; LIPOPHILICITY; MYALGIA; PAIN; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RHABDOMYOLYSIS; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0037262222     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.HDX.0000050417.89309.F8     Document Type: Article

References (46)

1. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-364.
2. Frick MH, Elo O, Haapa K, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-1245.
3. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels (the long-term intervention with pravastatin in ischaemic disease [LIPID] study group). N Engl J Med 1998;339:1349-1357.
4. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
5. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-1389.
6. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
7. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women width average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas coronary atherosclerosis prevention study. JAMA 1998;279:1615-1622.
8. Schwartz GC, Olsson AG, Ezkowitz MD, et al. Effects Of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study. JAMA 2001;285:1711-1718.
9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection. Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22.
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (adult treatment panel III). JAMA 2001;285:2486-2497.
11. Fonarow GC, French WJ, Parsons LS, et al for the National Registry of Myocardial Infarction 3 Participants. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction. Circulation 2001;103:38-44.
12. Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med 1999;14:711-717.
13. Hoerger TJ, Bala MV, Bray JW, et al. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol 1998;82:61-65.
14. Pearson TA, Laurora I, Chu H, et al. The Lipid Treatment Assessment Project (L-TAP). Arch Intern Med 2000;160:459-467.
15. Igel M, Sudhop T, von Bergmann K. Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin. J Clin Pharmacol 2002;42:835-845.
16. Watanabe M, Koike H, Ishiba T, et al. Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrolc-substituted 3,5-dihydroxy-6 heptenoates, a novel series of HMG-CoA reductase inhibitors. Bioorg Med Chem 1997;5:437-444.
17. White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002;42:963-970.
18. Buckett L, Ballard P, Davidson R, et al. Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus nonhepatic cells (abstract MoP29:W6). XIIth International Symposium on Atherosclerosis. Stockholm, June 25-29, 2000. Atherosclerosis 2000;151(special issue):41.
19. Chapman MJ, McTaggart F. Optimizing the pharmacology of statins: characteristics of rosuvastatin. Atherosclerosis 2002;(Suppl 2):33-37.
20. Farnier M, Davignon J. Current and future treatment of hyperlipidemia: the role of statins. Am J Cardiol 1998;82:3J-10J.
21. Stalker TJ, Lefer AM, Scalia R. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br J Pharmacol 2001;133:406-412.
22. McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001;87:28B-32B.
23. Chong PH, Yim BT. Rosuvastatin for the treatment of patients with hypercholesterolemia. Ann Pharmacother 2002;36:93-101.
24. Warwick MJ, Dane AL, Raza A, et al. Single- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522 (abstract MoP19:W6). XIIth International Symposium on Atherosclerosis. Stockholm, June 25-29, 2000. Atherosclerosis 2000;151(special issue):39.
25. Martin PD, Dane AL, Schneck DW, et al. Disposition of new HMG-CoA reductase inhibitor ZD4522 following dosing in healthy subjects [abstract]. J Clin Pharmacol 2000;40:1056.
26. Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of new HMG-CoA reductase inhibitor ZD4522 after AM and PM administration in healthy subjects [abstract]. J Clin Pharmacol 2000;40:1056.
27. Roach AE, Tsikouris JP, Haase KK. Rosuvastatin. A new HMG-CoA reductase inhibitor for hypercholesterolemia. Formulary 2002;37:179-185.
28. McCormick AD, McKillop D, Butters CJ, et al. ZD4522 - An HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: Metabolic studies in human in vitro systems [abstract]. J Clin Pharmacol 2000;40:1055.
29. Smith G, Davidson R, Bloor S, et al. Pharmacological properties of ZD4S22 - a new HMG CoA reductase inhibitor [abstract]. Atherosclerosis 2000;151:39.
30. Martin PD, Dane AL, Nwose D, et al. Effects of age and gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. Clin Pharmacol Ther 2001;69:P56.
31. Simonson SG, Martin PD, Mitchell PD, et al. Pharmacokinetics and pharmacodynamics of rosuvastatin in hepatically impaired subjects. Clin Pharmacol Ther 2001;69:86.
32. Olsson AG, Pears J, McKellar J, et al. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001;88:504-508.
33. Paoletti R, Fahmy M, Mahla G, et al. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolemic patients: a randomized, double-blind study. J Cardiovasc Risk 8:383-390.
34. Davidson M, Ma P, Stein EA, et al. Comparison of effects of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 2002;89:268-275.
35. Olsson A, Southworth H, Wilpshaar JW. Long-term efficacy and safety of rosuvastatin: results of a 52-week comparator-controlled trial versus atorvastatin [abstract]. Eur Heart J 2001;22(Suppl):253.
36. Brown WV, Chitra RK, Zedler BK, et al. Long-term efficacy and safety of rosuvastatin: results of a 52-week comparator-controlled trial versus pravastatin and simvastatin [abstract]. Eur Heart J 2001;22(Suppl):270.
37. Hunninghake DB, Chitra RR, Simonson SG, et al. Treatment of hypertriglyceridemic patients with rosuvastatin. Diabetes 2001;50:A143.
38. Stein E, Strutt KL, Miller E, et al. ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia [abstract]. J Am Coll Cardiol 2001;37(Suppl):292A.
39. Shepherd J, Hunninghake D, Harris S, et al. A review of the safety profile of rosuvastatin in an international phase II/III clinical trial program. Paper presented at the XIV International Symposium on Drugs Affecting Lipid Metabolism; New York, NY; September, 2001.
40. Cooper KJ, Martin PD, Dane AL, et al. Erythromycin has no clinically relevant effect on the pharmacokinetics of rosuvastatin. Abstract 287, Pharmacol Toxicol 2001;89(Suppl 1):75.
41. Cooper KJ, Martin PD, Dane AL, et al. Fluconazole has no clinically relevant effect on the pharmacokenetics of rosuvastatin. Abstract 288. Pharmacol Toxicol 2001;89(Suppl 1):75.
42. Martin PD, Cooper KJ, Dane AL, et al. Ketoconazole has no clinically relevant effect on the pharmacokinetics of rosuvastatin. Abstract 286. Pharmacol Toxicol 2001;89(Suppl 1):75.
43. Martin PD, Cooper KJ, Dane AL, et al. Itraconazole produces modest increases in rosuvastatin plasma concentrations [abstract]. Pharmacol Toxicol 2001;89(Suppl 1):77.
44. Kemp J, Martin P, Olise MD. Coadministration of rosuvastatin does not alter the pharmacokinetics of digoxin. Pharmacotherapy 2001;21:1255.
45. Durrington PN, Tuomilehto J, Hamann A, et al. Effects of rosuvastatin alone and in combination with fenofibrate on lipid subtractions in patients with type 2 diabetes: results at 24 weeks [abstract]. Circulation 2001;104(Suppl II):177.
46. nd ed. New York: McGraw Hill, 2003.